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Summary 
Transthyretin (TTR) transports thyroid hormones (THs), thyroxine (T4) and 
triiodothyronine (T3) in the blood of vertebrates. TH-binding sites are highly conserved 
in vertebrate TTR however, piscine TTR has a longer N-terminus which is thought to 
influence TH-binding affinity and may influence TTR stability. We produced 
recombinant wild-type sea bream TTR (sbTTRWT) plus two mutants in which six 
(sbTTRM6) and twelve (sbTTRM12) N-terminal residues were removed. Ligand-
binding studies revealed similar affinities for T3 (Kd=10.6±1.7nM) and T4 
(Kd=9.8±0.97nM) binding to sbTTRWT. Affinity for THs was unaltered in sbTTRM12 
but sbTTRM6 had poorer affinity for T4 (Kd=252.3±15.8nM) implying that some 
residues in the N-terminus can influence T4 binding. sbTTRM6 inhibited acid-mediated 
fibril formation in vitro as shown by fluorometric measurements using thioflavine-T. In 
contrast, fibril formation by sbTTRM12 was significant, probably due to decreased 
stability of the tetramer. Such studies also suggested that sbTTRWT is more resistant to 
fibril formation than human TTR.  
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Introduction 
Transthyretin (TTR) is one of several thyroid hormone binding proteins (THBP) which 
transport thyroid hormones thyroxine (T4) and triiodothyronine (T3) in the circulation of 
vertebrates. This protein is synthesized and secreted mainly by the liver and its 
functionally active form is a tetramer, the central core of which is proposed to transport 
one or two molecules of thyroid hormones (THs)(Blake et al., 1978, Schreiber and 
Richardson, 1997, Wojtczak et al., 1996). Subsequently TTR was also identified in the 
choroid plexus of mammals where it is proposed to play an important role in the 
transport of T4 across the blood brain barrier (Blay et al., 1993, Chanoine et al., 1992, 
Hamberger et al., 1990, Harms et al., 1991, Schreiber et al., 1990, Southwell et al., 
1993).  
The TTR tetramer is a highly stable protein, however dissociation and misfolding of this 
protein can lead to its conversion into insoluble amyloid structures that can deposit 
extracellularly. This process is associated with severe amyloid disease in humans: 
familial amyloid polyneuropathy (FAP) and senile systemic amyloidosis (SSA) 
(reviewed in Benson and Uemichi, 1996, Ingenbleek and Young, 1994, Schreiber and 
Richardson, 1997, Sipe, 1992). Tetramer dissociation seems to be the critical step in 
misfolding and in vitro studies have shown that the TTR tetramer can form fibrils under 
acidic conditions at 37ºC (Hammarstrom et al., 2001, Lai et al., 1996). 
TTR has now been identified in most vertebrate groups; it is present in placental 
mammals, Australian and American marsupials, birds, reptiles, amphibians and fish 
(Dickson et al., 1985, Duan et al., 1991, Duan et al., 1995, Larsson et al., 1985, Mita et 
al., 1984, Prapunpoj et al., 2002, Prapunpoj et al., 2000, Richardson et al., 1994, 
Richardson et al., 1997, Santos and Power, 1996, Santos and Power, 1999, Yamauchi et 
al., 1993, Yamauchi et al., 1999). Moreover, recently a family of transthyretin-like 
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proteins (TLPs) has been identified in bacteria, plants and animals including 
nonvertebrates and vertebrates(Eneqvist et al., 2003, Hennebry et al., 2006a). It has 
been suggested that the TTR gene, only present in vertebrates, probably arose as a 
results of a duplication of the ancestral TLP gene (Hennebry et al., 2006a, Prapunpoj et 
al., 2000, Richardson, 2002). Existent studies indicate an overall structural conservation 
between TLP and TTR (Hennebry et al., 2006b, Lundberg et al., 2006) however no 
evidence of TH binding ability could be found for TLP (Eneqvist et al., 2003). Such 
observations have led to the suggestion that TTR is a vertebrate innovation and evolved 
as a TH binder. 
The distribution of TTR in blood, liver and the choroid plexus of different vertebrates 
are variable, making it difficult to establish a consensual model for the evolution of this 
gene. For example, TTR is present principally in the liver and to a lesser extent in the 
brain and other tissue of teleost fish (Power et al., 2000, Santos and Power, 1996, 
Santos and Power, 1999) but in turtles (Trachemys scripta) it is expressed principally in 
the choroid plexus (Richardson et al., 1997). Moreover, some metatherian (marsupial) 
species contain TTR in the blood stream, whereas other do not (Richardson et al., 
1994). In addition to differences in tissue distribution of TTR between species, 
differences in the thyroid hormone binding properties of the protein have also been 
observed. The resolution of the crystal structure of human, chicken and rat TTR has 
revealed that the functional tetramer contains two structurally identical binding sites in 
the central channel(Blake et al., 1974, Hamilton et al., 1993, Sunde et al., 1996, 
Wojtczak, 1997, Wojtczak et al., 1992). The amino acids that are thought to be involved 
in T4 binding in the central channel of TTR appear to have been conserved between 
mammals and lower vertebrates. However, binding studies of plasma TTR with 
radiolabelled T4 and T3 have established that mammalian TTR has the highest affinity 
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for T4 while avian TTR preferentially binds T3 (Chang et al., 1999). Similar preferences 
for T3 were found for this protein in crocodile (Prapunpoj et al., 2002) and amphibians 
(Prapunpoj et al., 2000, Yamauchi et al., 1993). The molecular basis for the different 
affinity of mammalian and lower vertebrate TTR for the thyroid hormones remains to 
be established but it has been proposed that changes in the N-terminus of the protein 
may be an important factor. This region is the least conserved between species and in 
birds, reptiles or amphibian it is longer, having three additional amino acids, and is 
more hydrophobic than mammalian TTR (Aldred et al., 1997). The identification of 
TTR in teleost fish is relatively recent, the protein was isolated and the N-terminus 
sequenced from juvenile Masu salmon (Onchorhynchus masou) plasma (Yamauchi et 
al., 1999) and a full-length cDNA for seabream TTR was isolated from the liver of 
juvenile seabream (Santos and Power, 1996, Santos and Power, 1999). Ligand-binding 
studies with Masu salmon TTR revealed that it has three times higher affinity for T3 
(Kd=13.8nM) compared to T4 (Kd between 40-50nM) (Yamauchi et al., 1999). The 
crystal structure of sea bream TTR has been determined and showed that the overall 
topology of seabream TTR is conserved (Eneqvist et al., 2004, Folli et al., 2003). The 
thyroid hormone binding site is also highly conserved, although Ser 117 (human 
sequence) is substituted by Thr in sea bream TTR (Folli et al., 2003). Taking into 
consideration structural studies of human TTR in complex with L-thyroxine it seems 
unlikely that this substitution will affect TH binding (Wojtczak et al., 2001). However, 
preliminary qualitative binding studies suggest sea bream TTR preferentially binds T3. 
Despite conservation of TTR structure between sea bream and other vertebrates, the 
surface potential, most noticeably in the thyroid hormone-binding site is more negative 
in the sea bream and the N-terminus of the protein is longer (Power et al., 2000).  
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As a first step to understanding the basis for the differing hormone affinities between 
fish and mammalian TTR, wild type and N-terminal mutant sea bream TTRs were 
produced. A specific ligand-binding assay was developed and TH:TTR interactions 
characterised. Also, the consequences of N-terminal mutations for acid-mediated TTR 
fibril formation were assessed. Such studies may help to elucidate the regions of the 
molecule which are important for TTR’s TH binding preference and provide 
preliminary evidence about the role of the N-terminus in tetramer stability.   
 
 
Materials and Methods 
Cloning of sea bream TTRWT and mutants  
For production of sbTTRWT a vector pET 24d(+) construct was used (Eneqvist et al., 
2004) containing the mature protein encoding gene (lacking the signal sequence of 18 
amino acids predicted by SignalP v3.0 WWW Server (Bendtsen et al., 2004, Nielsen et 
al., 1997) preceded by a methionine as indicated 1MAPTPTDKHGGSDTRCPL18. 
Production of the mutant proteins was based on amplification by PCR of the full-length 
sea bream TTR cDNA in pBluescript SK(+) (Santos and Power, 1999) using primers 
strategically designed to introduce the desired mutations. The primers (described in 
Table 1) introduced a restriction enzyme site 5’ NheI flanking the vector’s N-terminal 
methionine and a BamH I 3’cleavage site following the C-terminal stop codon. Two 
mutated sequences relative to the WT construct were produced which omitted 
respectively 6 and 12 amino acids from the N-terminus of the mature protein. This 
strategy also caused a modification of the starting amino acids of the mutated sequences 
from MAP to MAS. The mutants were named sbTTRM6 (N-terminal sequence 
MASGGSDTR in which amino acids between positions 3 and 10 were deleted) and 
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sbTTRM12 (N-terminal sequence MASCPL in which amino acids between positions 3 
and 16 were deleted). The initial amino acids after methionine, alanine and serine which 
are small and poorly charged did not cause significant alterations in the hydrophobicity 
profile of this region as predicted by Protscale tool 
http://www.expasy.ch/tools/protscale.html. The PCR reaction products were ligated 
using T4 DNA ligase Ready-To-Go kit (Amersham Biosciences, UK) into pET 24b(+) 
vector (Novagen, Germany) which had been cut with the appropriate restriction 
enzymes to generate compatible ends. The recombinant vector was used to transform 
(Hanahan, 1983) E. coli BL21 pLySs (Novagen) which were then plated on LB agar 
plates containing 30 µg.ml-1 kanamycin and 34 µg.ml-1 cloramphenicol. Plasmid DNA 
was isolated from the bacterial culture using the alkaline lysis method (Birnboim and 
Doly, 1979) and the appropriateness of constructs confirmed by restriction digest and 
DNA sequencing (Macrogen, Korea). 
 
Protein expression 
Competent E. coli BL21 pLysS transformed with pET24b (+) vector containing the 
seabream TTR (WT, M6 or M12) constructs were plated on LB agar plates containing 
30 µg ml-1 kanamycin and 34 µg ml-1 chloramphenicol. For protein expression a pre-
culture was prepared by placing a single colony in 10ml LB broth with the appropriate 
antibiotic and growing overnight at 37ºC. The pre-culture was then diluted in LB broth 
to a final optical density (OD600nm) of 0.05 (250mL in a 1L flask) and the culture grown 
at 37ºC with vigorous agitation (250 rpm) until the OD600nm reached 0.6-1.0 
(approximately 2h). At this stage protein production was induced by adding 
isopropylthiogalactoside (0.2mM, IPTG, Sigma-Aldrich, Madrid, Spain) to the culture 
and incubating it for a further 3 hours at 30ºC. Bacteria were harvested by 
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centrifugation at 4500 g for 20 minutes and the pellet frozen until used for protein 
purification. Frozen bacteria were thawed and resuspended in 10 mL double distilled 
water containing phenylmethylsulphonylfluoride (PMSF) 1mM (Sigma-Aldrich). Lysis 
was induced by adding approximately 1 mg lysozyme (Sigma-Aldrich) plus 1mM 
MgCl2 and incubating on ice for a further 10 minutes. DNase I (5U/µL, Amersham 
Biosciences) was subsequently added followed by incubation for another 10 minutes. 
Supernatant and cell membranes were separated by centrifugation at 25 000 g for 15 
minutes at 4ºC. The supernatant was collected and stored at –80º C until required.   
 
Purification of recombinant sbTTRs 
Purification of the wild type and mutant proteins was achieved using a preparative 
continuous-elution electrophoresis system (Model 491Prep Cell, Bio-Rad laboratories). 
The supernatant (~8 ml) containing the recombinant protein was loaded onto a 
cylindrical preparative native Ornstein-Davis polyacrylamide gel (Davis, 1964, 
Ornstein, 1964), after mixing with sample buffer (0.0625 M Tris-HCl pH 6.8; 0.025% 
bromophenol blue; 10% glycerol). The resolving gel (75 x 37mm) was composed of 
10% polyacrylamide in 0.375 M Tris-HCl, pH 8.8. The stacking gel (25 x 37mm) was 
of 4% polyacrylamide in 0.125 M Tris-HCl, pH 6.8. Native electrophoresis was carried 
out at a constant power of 300V/60mA/12W over approximately 10h maintaining a 
constant temperature (18ºC) and using 0.025 M Tris-HCl, 0.192M glycine buffer, pH 
8.3 as the running buffer. Proteins fractionated on the polyacrylamide gel were allowed 
to migrate off the end of the gel, passed into an elution chamber and were then collected 
as individual fractions (2.5ml) at 8oC (Valkonen et al., 2001). These fractions were 
analyzed by SDS-PAGE (15% polyacrylamide) and silver stained in order to identify 
those containing the purified sbTTR. Fractions containing pure sea bream TTR were 
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9 
pooled, dialysed against 50mM Tris pH 7.5 and concentrated by centrifugation (1900 
g), using filtration columns Ultrafree 15, Biomax 5 MWCO (Millipore, UK). The use of 
native conditions and further dialysis of the samples was essential to ensure that the 
protein retained its native tetramer conformation and therefore its ability to bind the 
hormone. Protein purified in denaturing conditions had a reduced binding capacity in 
ligand binding assays even after renaturing treatment. The concentration of the purified 
protein was determined using a modification of the Lowry method (Lowry et al., 1951). 
The molar extinction coefficient of the recombinant protein at 280nm was also 
calculated (Layne, 1957). 
 
Antibody Production 
The production of a polyclonal sbTTR antibody was carried out in rabbits by Agrisera 
(Sweden). Purified recombinant sbTTR (~ 1mg in water) was sent on ice to Agrisera 
and was used to immunize a rabbit following the standard protocol 
(www.agrisera.com). In brief, the rabbit utilized for antisera production was immunized 
4 times with the solution of recombinant protein (~ 250µg per immunization) over 14 
weeks. After the third immunisation a small blood sample was obtained from the rabbit 
and was tested together with a sample of pre-immune serum (as a negative control) by 
Western blot to assess the titer and specificity of the antisera for seabream TTR.  
 
Western Blot Analysis 
Purified recombinant seabream TTR was fractionated by SDS-PAGE (15% 
polyacrylamide gel) and transferred to a hydrophobic polyvinylidene difluoride 
membrane (Hybond-P, Amersham Biosiences). The membrane was incubated with 
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blocking solution (10% (w/v) milk; 0.1% (v/v) Tween-20 in 1x phosphate buffered 
saline, PBS), overnight with constant agitation at 4ºC. Membranes containing 
recombinant sbTTR were incubated with 1/10000 dilution in 1x PBS of rabbit anti-
sbTTR sera for 2h at room temperature. Excess antisera was removed and the 
membranes were washed 3 x 5 minutes in PBS/Tween 20 0.05% prior to addition of the 
secondary antibody (anti-rabbit IgG-peroxidase anti-peroxidase 1/5000). Membranes 
were incubated with secondary antibody at room temperature for 1h with constant 
agitation. Membranes were washed 2 x 10 minutes in PBS/Tween 20 prior to 
development with 3,3’-diaminobenzidine (DAB, 20mg) and 0.003% H2O2; the signal 
was intensified by addition of 10mg of Nickel in 1xPBS and the colour reaction stopped 
by transferring the membrane to water.  
 
Determination of molecular mass of recombinant proteins by HPLC 
HPLC/gel filtration was used to estimate the molecular masses of wild type and mutant 
TTRs. The chromatographic procedure was carried out with an autosampler (Merck-
Hitachi AS-2000 A) coupled to a UV detector (Merck-Hitachi L4000) using a Bio-Sil 
SEC250 column (Bio-Rad) equilibrated in 0.1M sodium phosphate buffer with 0.2 M 
NaCl at pH 6.8 prepared with milliQ water and previously filtered (0.2 µM pore size) 
and degassed. The column was first calibrated by injection of a 100 µL sample of 
protein standards (Bio-Rad) containing Thyroglobulin (670 KDa), Bovine gamma-
globulin (158 KDa), Chicken ovalbumin (44 KDa), Equine myoglobulin (17 KDa) and 
Vitamin B12 (1.35 KDa). Subsequently a 100 µL sample of each pure recombinant 
protein (~1mg/ml) was injected in series onto the column. Separation was carried out 
with a flow of 0.5 ml/minute and the absorbance at 280nm was registered over 40 
minutes.   
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Circular Dichroism 
Far-UV CD spectra were recorded between 190-250 nm for sbTTRWT, M6 and M12 
and purified human TTR (purified as previously described (Karlsson et al., 2005)) 
employing a CD spectrometer (Applied photophysics Π*-180, UK). A 1mm path length 
quartz cell with a protein sample of ~16 µM (~1mg/ml) was used. The buffer baseline 
spectrum was subtracted from all spectra. Results were expressed in mean residue 
weight ellipticity ([θ]mrw λ) in deg cm2/dmol using the equation: [θ]mrw, λ= MRW (θ λ)/10 
l c in which MRW is the mean residue weight (Molecular weight/N-1 where N is the 
number of amino acids); θ is the observed ellipticity (in degrees), l is the path length (in 
cm) and c the protein concentration (in g/ml). 
 
Analysis of [125I] T3 binding by native glycine-acetate gel electrophoresis 
In order to conduct a provisional analysis of the thyroid hormone binding ability of 
sbTTRWT, M6 and M12, the purified proteins were incubated on ice for 1h with 
[125I]T3, as T3 had previously been suggested to strongly bind fish TTR (Santos and 
Power, 1999, Yamauchi et al., 1999). A parallel reaction with [125I]-T4 (0.01 µCi) and a 
human plasma (1.5µl) sample which contained albumin (67 kDa) that binds T4 was also 
conducted. The samples were then separated by electrophoresis on a 12.5% native 
glycine-acetate gel at 60 mA in glycine-acetate 1X running buffer (Glycine 0.2M; 
Sodium Acetate 0.12 M, pH 8.6). Samples contained 25µL protein, plus 5 µL of 50% 
glycerol and 5 µL of glycine-acetate 5X running buffer (Glycine 1M; Sodium Acetate 
0.64 M, pH 8.6) and finally 1 µL of labeled hormone (0.01µCi). The resulting gel was 
dried (Drygel.jr se540, Hoeffer Scientific Instruments, UK) and exposed for 48h at -
80ºC to Kodak RX film in a cassette containing an intensifying screen.  
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Determination of the dissociation constant of T3 and T4 binding to recombinant WT and 
mutant TTRs  
Binding assays previously developed and reported in the literature (Almeida and 
Saraiva, 1996, Hamers et al., 2006) for none piscine TTR failed to give significant TH 
binding with sbTTR. For this reason a ligand-binding assay was developed using 
sbTTRWT and T4 and T3 in order to characterise hormone binding kinetics. Optimal 
assay conditions were established by testing various buffers, incubation times, 
temperatures and separation methods. In each assay, duplicate tubes were utilised and 
experiments were repeated at least three times. Several concentrations of sbTTRWT 
(0.05, 0.15, 0.25 and 0.5 µg) were incubated in TCN buffer (20mn Tris/HCl, pH 7.5, 
93mM NaCl, 1mM CaCl2 and 1mM MgCl2), containing 0.1nM [125I]-T3 in the presence 
or absence of an excess of 10µM unlabeled T3 (to assess non-specific binding) for 2h on 
ice in order to establish the optimal protein concentration for the assay. Separation of 
free and TTR bound [125I]-T3 was carried out by adding to assay tubes 25µL of 
125µg/ml bovine γ-globulin and 250µL of 25% (w/v) PEG 6000 containing 0.2M ZnCl2 
in TCN buffer (Yamauchi et al., 1993). The mixture was centrifuged at 1500 g for 10 
minutes at 4ºC and the resulting pellet washed with 1ml of 12.5% (w/v) PEG 6000 
containing 0.1M ZnCl2 and counted in a gamma counter (Wizard, Pharmacia-LKB). For 
the competition binding studies 50ng/200µL of recombinant proteins (sbTTRWT, M6 
and M12) were incubated in the same conditions, in the presence and absence of 
increasing concentrations (0-10µM) of unlabeled hormone. The same separation method 
was used and percentage of binding of TH to sbTTRWT was determined relative to the 
maximum TH binding obtained in the absence of competitor. To determine dissociation 
constants of T3 and T4 binding to TTRWT, M6 and M12, Scatchard plots were derived 
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from displacement curves using the software Kell-Radlig from Biosoft, UK. The 
existence of significant differences in the IC50 and Kd values obtained from competition 
assays and Scatchard analysis of TTRWT, M6 and M12 were determined by One Way 
Analysis of Variance (ANOVA) and multiple comparison procedures (Tukey Test). 
Differences were considered statistically significant at p<0.05. All the statistical 
analysis was performed using Sigma Stat software version 3 (SPSS).  
 
 
Fibril formation under acidic conditions 
Production of fibrils by TTR was assessed at several different pH values: pH7 (control), 
pH 5.5, pH 4.5 and pH 3.5 using previously described methods (Colon and Kelly, 1992, 
Hammarstrom et al., 2001, Lai et al., 1996). Theoretical values for the isoelectric point 
(Ip) of M6 (Ip=5.59) and M12 (Ip=5.58) were estimated using Protscale tool 
(http://www.expasy.ch/tools/protscale.html) and found to not differ greatly from the 
WT (Ip=5.73). Briefly, TTR samples (WT and mutants) were diluted to a concentration 
of 0.1-0.2mg/mL which is close to the mammalian physiological average in blood 
(0.2mg/mL). Acetate buffers used for dilution (NaOAC 50mM, KCl 100mM) were 
prepared and adjusted to the desired pH with NaOH or HCl. Samples were incubated at 
37ºC for 72h and fibrils were collected by centrifugation at 14000 g for 30 minutes. The 
resulting pellet was carefully resupended in 1 mL of a buffer solution with Thioflavine 
T (ThT) (Tris 50mM, 100mM KCl, ThT 10µM) prepared immediately before use. To 
quantify the fibril aggregates in solution, fluorescence measurements were recorded in a 
Fluoromax 3 spectrofluorometer (Jobin Yvon, Horiba) using a 1cm path length quartz 
cell. Excitation and emission slit width was of 5nm. The excitation wavelength was set 
at 450nm and the emission spectrum recorded between 460-600nm. Emission at 482 nm 
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is characteristic of ThT bound to protein fibrils and is proportional to the quantity in 
solution (Naiki et al., 1989). The final spectrum was obtained after subtraction of the 
ThT baseline spectrum and further dividing by the exact concentration of each protein.  
The existence of significant differences between samples was assessed by Two Way 
ANOVA and multiple comparisons (Holm-Sidak method) analysis using Sigma Stat 
software version 3 (SPSS). Differences were considered statistically significant at 
p<0.05. 
 
Results 
Expression and purification of recombinant sbTTRWT and mutants 
Sequencing of TTR expression vector constructs confirmed that sbTTRWT and the 2 
mutants M6 and M12 were successfully ligated into vectors and were in frame. 
Optimization studies of recombinant protein expression with sbTTRWT revealed that a 
0.2mM IPTG concentration and 3h incubation post-induction at 30ºC were appropriate 
conditions for induction. Expression was carried out in E. coli BL21DE3pLysS strain 
and recombinant protein analysed using denaturing SDS-PAGE 15% followed by 
western blotting (not shown). A single immunoreactive protein was identified in 
bacterial lysates with rabbit sbTTR antiserum. Bacteria (BL21DE3pLysS) transformed 
with the expression vector pET 24b+ without a sbTTRWT insert and vector 
pET24b+/sbTTRWT but without IPTG induction were used as controls and did not 
express the protein. The same expression conditions were used for production of the 
mutants sbTTRM6 and sbTTRM12.   
Analysis of purified proteins by denaturing SDS-PAGE (15% polyacrylamide) revealed 
that the monomeric sbTTRs were close to the predicted molecular mass of 12.8, 13.4 
and 14.2 KDa for sbTTRM12, sbTTRM6 and sbTTRWT, respectively (Fig. 1A). 
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Analysis of the purified recombinant proteins was also carried out in native conditions 
by PAGE (10% polyacrylamide) electrophoresis followed by silver staining. Single 
bands most likely corresponding to native TTRs were detected in sbTTRM12, M6 and 
WT purified samples (Fig.1B). Both monomeric and native tetramers of WT and mutant 
TTRs were immunoreactive with sbTTRWT antisera as revealed by Western blot (Fig. 
1C and D). 
Native recombinant sbTTRWT and mutants molecular mass 
The functional form of TTR is a tetramer and this structure is required to bind THs. 
Therefore, before proceeding with TTR-TH binding studies HPLC/gel chromatography 
was performed in order to determine if the molecular mass of sbTTRWT and mutants 
correspond to that expected for TTR tetramers. The retention time of piscine 
recombinant proteins in gel filtration chromatography was of 16.13 min for sbTTRWT, 
16.26 min for M6 and 17.43 min M12 which corresponded to a molecular mass of 57, 
53 and 51 kDa, respectively. The molecular mass obtained for all recombinant piscine 
proteins corresponded to the molecular weights predicted for the tetrameric 
conformation. This was further confirmed by comparison to recombinant human TTR 
(Fig. 2A) which had a retention time (15.9 min) close to the recombinant piscine 
proteins. These results strongly suggest that all the pure sea bream recombinant proteins 
used in the ligand binding assays were in the correct active tetramer conformation. 
Nevertheless it is worth noticing that the HPLC chromatogram of some batches of the 
mutant M12 protein, revealed both the tetrameric and monomeric conformations in the 
sample (Fig. 2B). This observation suggests that the M12 mutation decreases the 
stability of the tetramer. The cause of the shift in equilibrium towards the monomer with 
the M12 mutation compared to WT and M6 proteins was not determined but may be 
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related to changes in protein concentration among different batches of recombinant 
protein. 
 
sbTTRWT and mutants secondary structure 
Circular Dichroism spectra were recorded to give insight into the secondary structure of 
sbTTRWT, the mutants and the sample of human TTR. All the proteins had spectra 
which indicated they possessed secondary structure (Fig. 3). The software CDSSTR 
available in the RCSB Protein Database (www.rcsb.org.) was used to compare spectra 
of all the proteins and a perfect curve fit was obtained. The same software was used to 
calculate the percentage of structure types for all the proteins. α, β and unordered 
structure percentages were quite similar for sbTTRWT, mutants and human TTR. 
Moreover, comparison of the percentage of α, β and unordered structures in sbTTRWT, 
the mutants and human TTR, to the structures of recombinant TTRs deposited in the 
Protein Database (www.rcsb.org.) (Eneqvist et al., 2004, Folli et al., 2003) revealed 
they were very similar. Overall these results strongly indicate that all the recombinant 
TTRs have the expected secondary structure and the mutations introduced did not cause 
significant modifications. 
 
Analysis of [125 I] T3 binding by native glycine-acetate gel electrophoresis 
The native PAGE autoradiographic patterns after 48h exposure are shown on Fig. 4. 
After pre-incubation of TTR with labeled [125I]T3, different gel migration patterns were 
detected for the labeled hormone. [125I]T3 alone migrated close to the electrophoretic 
front, [125I]T3 bound to WT and both mutant TTRs had a retarded migration and 
migrated in a position characteristic of the tetrameric proteins as previously reported by 
the authors (Santos and Power, 1999). The results indicate that wild type and both 
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mutant TTRs bind [125I]T3 in the solid phase assay. The sample of human plasma 
incubated with [125I]T4 also revealed one strong band likely corresponding to HSA. TTR 
typically migrates slightly faster than albumin in native electrophoresis, hence its 
previous name, pre-albumin. In the present study the recombinant WT and mutant TTRs 
showed the expected mobility in non-denaturing gels providing further evidence that 
they retained the native TTR conformation.  
 
THs binding to sbTTRWT and mutants 
In order to establish the optimal concentration of protein for sbTTR binding assays, four 
different concentrations of sbTTRWT were tested. [125I]T3 binding was found to 
increase up to a protein concentration of 0.125µg/tube, after which only a modest 
increase was observed (Fig. 5A). A concentration of recombinant protein of 0.05µg/tube 
was found efficient and was used thereafter for all binding assays with wild type and 
mutant sbTTR.  
The competitive binding assays revealed that [125I]T3 binding to sbTTRWT was 
displaced both by increasing unlabeled  T3 and T4 with similar IC50 values (Fig. 5B and 
Table2). Also, Kd values found for both thyroid hormones (Fig 6A and B and Table 2) 
binding to sbTTRWT were not significantly different (P>0.05). These results suggest 
sbTTRWT has a similar binding affinity for T3 and T4, in contrast to previous studies 
with piscine TTR which suggested it has a higher affinity for T3 than T4 (Santos and 
Power, 1999, Yamauchi et al., 1999).   
In order to test the effect of N-terminal deletions on the binding affinity of sbTTR to 
THs, parallel competition binding experiments were performed with the three proteins, 
sbTTRWT, sbTTRM6 and sbTTRM12 as previously described (see methods). Binding 
of [125I]T3 to WT and mutant sbTTRs was inhibited by unlabeled T3 in a similar way for 
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each of the proteins tested as shown by the almost overlapping competition curves and 
close IC50 values  (Fig.5C and table 2). This result seems to suggest that truncation of 
the N-terminal region of sbTTR has no major influence on T3 binding affinity.  
Specific binding of the proteins to T4 was also determined and no significant difference 
was found in the IC50 value of both in sbTTRWT and sbTTRM12 (Fig 5D and table2).  
However, a significantly (p<0.001) higher IC50 value (622 ± 98.9 nM) was obtained for 
T4 binding to the mutant sbTTRM6 when compared to sbTTRWT and sbTTRM12. In 
agreement with the preceding results, Scatchard analysis revealed close Kd values for 
sbTTRWT and sbTTRM12 binding to both T3 and T4 and for sbTTRM6 binding to T3 
(see Fig. 6C, D, E and table 2). However, again a significantly (p<0.001) higher 
dissociation constant of 252.3 ± 15.8 was found for sbTTRM6 binding to the hormone 
T4.  
Overall the results seem to indicate that N-terminal truncation does not affect the 
affinity of sbTTR to triiodothyronine (T3). Although the same cannot be said about its 
binding to thyroxin (T4) where intriguingly, removal of the first 6 N-terminal amino 
acids of sbTTR caused a great loss of affinity (approximately 25x lower), while removal 
of the first 12 amino acids caused no significant change (p>0.05) in binding affinity 
compared to sbTTRWT.  
 
Fibril formation by sbTTRWT and mutants 
Human TTRWT forms fibrils after incubation at 37ºC and low pH (Colon and Kelly, 
1992). In the present study sbTTRWT and N-terminal mutants were analysed for their 
ability to form fibrils in acidic conditions. The amount of fibril formation at 
increasingly acidic pH was monitored by fluorescence measurements of the dye 
Thioflavine T. Fibrillation of sbTTRWT at pH 3.5 is maximal and was taken as 100%. 
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The final result is depicted in Fig. 7 and shows that sbTTRWT, in common with human 
TTR, also has the ability to form fibrils in acidic conditions in vitro. However, the 
extent of fibril formation only increases dramatically at pH3.5 (p<0.001 when compared 
to pH7), whereas for the human protein, maximum fibrillation was found to occur at pH 
4.4. As for the mutant proteins, sbTTRM12 showed significant amyloidogenic 
properties at an even higher pH of 4.5 with no further increase at pH3.5. Interestingly, 
for the mutant sbTTRM6 no significant acid-induced fibril increase was found (p>0.05) 
even at pH 3.5 (p<0.001) compared to the WT at the same pH. It would appear that 
removal of the first 6 N-terminal amino acids of sbTTR (M6) appears to eliminate its 
amyloidogenic properties in acidic conditions.  
 
 
Discussion 
Evolution of transthyretin binding affinity for THs T3 and T4 
Over the last few years, TTR cDNA and amino acid sequences have been described for 
a number of representatives of different phylogenetic groups. Several studies 
concerning TTR affinity for the thyroid hormones T3 and T4 seem to indicate that 
during evolution TTR progressively lost its higher affinity for T3 in lower vertebrates 
and became a T4 binder in eutherian mammals (reviewed inPower et al., 2000). This 
evolution is consistent with physiologically advantageous adaptations regarding TH 
transport in which T4 acts as a precursor hormone liberated from the thyroid gland and 
conversion to T3 occurs in a tissue-specific manner and is regulated by deiodinases. 
Also, the strong affinity of TTR for T4 counteracts THs easy permeation into the 
intracellular compartment as a consequence of their lypophilic character. This notion 
has gained support from studies of T3 and T4 affinity for TTR in reptiles (Achen et al., 
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1993, Prapunpoj et al., 2002), amphibians and fish (Eneqvist et al., 2003, Santos and 
Power, 1999, Yamauchi et al., 1993, Yamauchi et al., 1999). However, values reported 
so far to describe affinities between TTRs and THs are very variable between studies 
even for the same proteins, probably as a consequence of assay methods and protein 
origin (serum or recombinant). Moreover, until now no quantitative analysis of TH 
affinity for sbTTR have been conducted although previous qualitative analysis using 
recombinant TTR (Eneqvist et al., 2003) or fish plasma (Santos and Power, 1999) in 
respectively, dot-blot or native gel electrophoresis revealed that T3 binds most strongly 
to sbTTR. In such a dot-blot assay however, no binding of T3 to human recombinant 
TTR was detected which may suggest that TH binding to recombinant TTRs may be 
weaker than to native TTR in serum. Moreover, the affinities of the THs for sbTTR in 
the preceding assays were based on the intensity of the radioactive signal which may 
depend on the assay and specific activity of the labelled hormones. sbTTR binding to T4 
has also been studied by fluorescence spectroscopy but no Kd values were reported 
(Folli et al., 2003).
 
In the present study the objective was to quantify sbTTR affinity for 
T3 or T4 and assess the effect of modifications in the N-terminus and as existing assays 
for other organisms failed to give significant hormone binding it was necessary to 
develop a specific competitive TH binding assay for sea bream TTR. The assay 
developed gave consistent and reproducible Kd values independent of other variables 
and revealed that sbTTR had a similar affinity for T3 and T4. The method developed is a 
liquid phase binding assay using a polyethylene glycol (PEG) precipitation method 
similar to that used with amphibian TTR (Yamauchi et al., 1993). When recombinant 
human TTR was used in the binding assay developed for piscine TTR, THs bound 
poorly (own observations) and the results obtained differed substantially from those 
previously published when using gel filtration separation method (Almeida and Saraiva, 
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1996, Hamers et al., 2006). This was found to be a consequence of the PEG separation 
method as when a conventional gel filtration separation method was used it gave Kd 
values (~60nM) within the normal range for human TTR (Chang et al., 1999). In 
contrast, gel filtration had a negative effect on TH binding by sbTTR, suggesting that 
the interaction of TH:TTR is very sensitive to separation conditions and this may 
explain the extreme variability of Kd values  reported by different authors for TTR from 
a number of organisms (eg. from 0.3 to 128 nm for human transthyretin and T4) (see 
Chang et al., 1999). In fact, in previous studies, piscine TTR purified from masu salmon 
plasma showed 3 times higher affinity for T3 than T4 (Yamauchi et al., 1999) and in this 
assay the separation method was based on ion exchange (Dowex method). Nevertheless, 
the difference in affinity of T3 and T4 binding to masu salmon TTR, was not as great as 
observed with other species, such as bullfrog where a 360 times greater affinity was 
found for T3 than T4 (Yamauchi et al., 1993). These observations taken together with the 
data presented here for sbTTR may indicate that fish TTR has similar affinities for both 
THs in contrast to what occurs in other vertebrates. In fact, structural analysis of TTRs 
seems to support this idea. Comparison of TTR sequences from representative species 
reveals a high degree of conservation in the amino acid sequence of this protein from 
eutherians, marsupials, birds and lizards (from 66 up to 85% sequence identity). 
However, sequence identity of TTR from the former species and amphibian and fish is 
considerably lower (from 48 to 55% in fish or 62% in amphibian) (Power et al., 2000). 
Moreover, comparative studies of three-dimensional structure models of human, rat, 
chicken and sea bream TTR, revealed a highly conserved tetrameric structure but a 
surface potential, especially at the TH binding site, more negative (close to -15 kT/e) in 
chicken and sea bream than human and rat (close to 0 kT/e) (Power et al., 2000).     
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It would appear that ancestral TTR has a preference for T3 but following the origin of 
amniotes it began to acquire a higher affinity for T4 instead. However in fish data seems 
to be inconsistent with this and an alternative evolutionary process may have occurred. 
Although the vast diversity of fishes makes generalizations difficult and highlights the 
need for further studies of TTR:TH binding in species representative of the main classes 
of fish. Moreover, studies of ancient species (hagfish and lamprey, from which TTR 
sequence has been recently determined Manzon et al., 2007) close to the divergence of 
the fishes from the lineage giving rise to tetrapods will be important to establish the TH 
binding characteristics of TTR in common ancestral vertebrates. The differing hormone 
affinity of TTR in modern teleosts compared to other vertebrates raises interesting 
questions about the functional significance of this change.  
 
Role of the N-terminal region on sbTTR binding  
Multiple amino acid sequence alignments of monomeric TTR from several species 
show a high degree of conservation for this protein. More specifically, it reveals that the 
amino acids predicted to be involved in the TH binding channel are almost 100% 
conserved during evolution, suggesting that TH binding is probably the most important 
function of the protein (Power et al., 2000). The N-terminal region of the polypeptide 
seems to be most variable showing progressive changes in length and hydropathy from 
fish to mammals. This segment is shorter and more hydrophilic in eutherians becoming 
longer and more hydrophobic in marsupials (with two additional amino acids), and in 
birds, reptile and amphibian (with three additional amino acids). These changes could 
be explained by splice site shifts of intron 1 as previously proposed (Aldred et al., 
1997), but their effect on protein function is not yet clear. A shorter and more 
hydrophilic tail seems to be coincident with an increase in affinity for T4. Moreover, the 
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fact that in the tetrameric structure, this region is situated at the entrance of the binding 
channel suggests that its size could influence TH access to the binding sites. These 
observations led to the hypothesis that the length and hydrophilic nature of the N-
terminus are important for TH binding properties of TTR.  
So far, binding studies involving recombinant chimeric xenopus/crocodile TTR and 
recently with human/crocodile TTR provided experimental evidence that this region 
influences TH binding affinity of TTR (Prapunpoj et al., 2006, Prapunpoj et al., 2002). 
In order to shed more light on this matter, in the present study, two mutated sbTTRs 
were produced, in which 6 (sbTTRM6) and 12 (sbTTRM12) amino acids were removed 
from the N-terminal region of the protein. The sbTTRM12 mutant maintained TH 
binding characteristics similar to the sbTTRWT, while the sbTTRM6 mutant had an 
approximately 25 times lower affinity for T4 but not for T3. This curious result could 
indicate that the size of the N-terminus is not directly related to the access of THs to the 
binding site as has been suggested (Power et al., 2000) but that hormone binding is 
probably most affected by the properties of the amino acids in this region. This 
influence could be due directly to the amino acids located in the extremity of the 
molecule, or because of the overall charge or conformation acquired by this region and 
interaction with the binding channel. Analysis of the hydrophobicity profile of sbTTR 
N-terminal sequence through Protscale tool at 
http://www.expasy.ch/tools/protscale.html and using the amino acid scale of Kyte & 
Doolittle shows that hydrophobicity increases towards the inside of the N-terminal 
sequence of the sbTTR monomer. Therefore, the N-terminus of sbTTRM12 is much 
more hydrophobic than in sbTTRM6 and even more than sbTTRWT, but only 
sbTTRM6 has less affinity for T4. Moreover, analysis of the N-terminal sequence of 
masu salmon TTR which has higher affinity for T3 (Yamauchi et al., 1999) reveals it 
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has a slightly more hydrophilic N-terminus than sbTTR. Together these results suggest 
that increased hydrophilicity per si is not directly associated with a higher affinity for T4 
and other factors must be taken in considerations when analysing the binding properties 
of TTR. 
Nonetheless the N-terminal region does appear to be important for determining 
hormone affinity, however, the X-ray structures of TTR do not give relevant data for the 
first N-terminal amino acids since this region does not form ordered structures. Also, in 
the electron density map of sbTTR, unidentified electron density was found in the 
centre of the channel which could correspond to N-terminal residues of the protein 
(Eneqvist et al., 2004). Structural studies also show that there are several amino acid 
substitutions in the hydrophobic core of piscine TTR compared to the human protein 
and that residue Val14 (close to the N-terminus) can affect the position of the otherwise 
conserved residues. Furthermore, Lys15, seems to play a crucial role in hormone 
binding to the protein. Lys15 together with Glu54 is located at the entrance of the 
channel and strongly interacts with THs (Blake and Oatley, 1977, Eneqvist et al., 2004). 
Such evidence suggests that amino acids located close to N-terminus can strongly 
influence the surrounding environment and thus affect hormone binding to the protein. 
Therefore it is not surprising that some amino acid modifications can cause strong 
affinity differences but at the same time other modifications have no effect. In 
conclusion, the results of the present study indicate that the N-terminal region plays an 
important role on TH binding ability of sbTTR. However, the results do not necessarily 
correlate with the binding evolution to T4, or with the size of the N-terminus tail but 
rather with an overall combination of specific amino acid properties. 
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N-terminal region and sbTTR stability 
Circular dichroism spectra in the far-UV region clearly reflect the high beta sheet 
content of sbTTR and show that truncation of 6 or 12 residues at the N-terminal do not 
disrupt the secondary structure of TTR. It is known that human TTR can form amyloid 
fibrils in acidic conditions. In vitro studies have shown that TTR forms fibrils upon 
incubation at low pH at 37ºC (Colon and Kelly, 1992). However, at physiological 
concentrations and pH it retains its native tetrameric structure. TTR amyloid begins to 
form only when tetramers dissociate into their monomeric intermediates that self 
assemble into fibrils (Damas et al., 1996, Hammarstrom et al., 2002, Lai et al., 1996, 
Quintas et al., 1999). Thus, the consensual approach to prevent amylodogenesis relies 
on stabilization of the tetrameric native conformation. Several studies have shown that 
the binding of many small molecules including the natural ligand T4 to TTR’s central 
channel favours tetramer fold stability reducing fibril formation (Adamski-Werner et al., 
2004, Klabunde et al., 2000, Miroy et al., 1996, Morais-De-Sa et al., 2004, Purkey et al., 
2001). So far, no particular region of the TTR molecule has been associated with its 
amyloidogenic properties, although previous findings strongly relate fibril formation 
with the central thyroid hormone-binding channel stability. In the present study we 
suggest that changes in the N-terminal region of the protein monomer can affect sbTTR 
affinity for THs by interfering with the properties of the binding channel. In this way, 
such changes might also affect tetramer stability and consequent fibril formation.  
Fluorimetric measurements of thioflavine T were used to compare the extent of fibril 
formation at different pH for sbTTRWT and the two N-terminal mutants M12 and M6. 
Interestingly, the mutant M6 that lost affinity for the hormone T4 seemed to be more 
stable and did not form fibrils at a pH as low as 3.5. Absence of fibrillation for the M6 
mutant is probably due to a high stability of the tetramer or alternatively to an 
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involvement of the first six amino acids in the fibrillation mechanism. Mutant M12 
showed a greater propensity to form fibrils and contrary to the wild type, fibrillation is 
very significant even at pH 4.5. The increased propensity for fibrillation of M12 is 
clearly a result of decreased stability of the tetramer which is apparent from the 
tendency of this mutant in some batches of recombinant protein and even under mild 
conditions to form monomers. This would be in accordance with the fact that formation 
of the monomer is a crucial step in the process of fibril formation as previously reported 
(Hammarstrom et al., 2002, Lai et al., 1996, Quintas et al., 1999). Dissociation of the 
tetrameric form of TTR is generally very difficult to achieve and has only been detected 
for human TTR under extreme conditions (6.75M Urea at 100ºC). Furthermore, for 
sbTTRWT and the M6 mutant no monomers were detected under physiological 
conditions showing that the equilibrium between tetramer and monomers is largely 
shifted to tetramer probably to prevent fibrillation. The greater resistance of sbTTRWT 
to fibril formation compared to previous studies of the human protein (Eneqvist et al., 
2003, Lai et al., 1996) makes further comparative analysis concerning TTR stability of 
great interest. Moreover, the possibility of relating a specific region with protein fibril 
formation may offer a means by which to combat this process, and it will be of great 
interest to investigate this further. 
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Table 1. Primers used for amplification of sbTTRWT and mutants M12 and M6.  
 
 Primers (5’→ 3’) 
 Forward Reverse 
sbTTRWT TTT TTC ATG ACC CCC ACC CCC ACG TTT CGA GCT CAC TCG TGT ACG CTG GAG 
sbTTRM12 GCT AGC TGT CCT CTG ATG GTA AAA ATC C GGA TCC TCA CTC GTG TAC GCT GGA GAC 
sbTTRM6 GCT AGC GGA GGC TCA GAC ACC AGG TG GGA TCC TCA CTC GTG TAC GCT GGA GAC 
 
Bold and underlined sequences represent the restriction enzyme sites for Nhe I and 
BamHI, respectively, introduced for correct insertion in the expression vector. 
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Table 2. Summary of IC50 and Kd values for recombinant sbTTRWT, M12 and M6 
binding to THs.  
 
Values are presented as mean ± SE for the sbTTRWT (n = 7 for IC50 and n=5 for Kd) 
and mutants (n = 3). One way ANOVA and multiple comparison Tukey test were used 
for comparison of all values within each kind of parameter (IC50 or Kd). Binding of T4 
to the mutant sbTTRM6 differed significantly in both IC50 and Kd values (*, p<0.001) 
from T4 binding to the other recombinant TTRs or T3 binding to all recombinant TTRs. 
Values were considered to be significantly different at p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
IC50 values  Kd values 
 
THs sbTTRWT sbTTRM12 sbTTRM6  sbTTRWT sbTTRM12 sbTTRM6 
T3 19,6±3,3nM 17,9±3,2 nM 21±1,9 nM  10,6±1,7nM 13,5±3,4nM 8,47 ± 0,4 nM 
T4 18,3±1,5nM 21,8±4,0 nM 622*±98,9nM  9,8 ±0,97nM 17,9±4,2nM 252,3*±15,8nM 
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Figure legends 
Figure 1. Analysis of purified recombinant sbTTRWT and mutants.  
A. SDS-PAGE 15% followed by silver staining of purified and concentrated 
recombinant proteins: sbTTRM12; sbTTRM6 and sbTTRWT. B. Analysis of purified 
and concentrated recombinant protein using Ornstein-Davis 10% native PAGE, 
followed by silver staining: sbTTRM12; sbTTRM6 and sbTTRWT. C and D. Western 
blot analysis of the same samples in denaturing and native PAGE respectively is shown 
below the corresponding figure. The samples were transferred to a PVDF membrane 
and immunostained using a primary antisera raised in rabbit against sbTTRWT 
(1:10000) and a secondary antisera against rabbit Ig conjugated to PAP (1:5000). Color 
development was carried out using 3,3’-diaminobenzidine (DAB).  
   
Figure 2. 
A. HPLC/gel chromatography of sbTTRWT and mutants M6 and M12. Observed peaks 
refer to retention times for each protein: sbTTRWT (16.13 min), M6 (16.26 min) and 
M12 (17.43 min). Correspondence to molecular weights is illustrated with an arrow 
based upon the approximate retention times for protein standards with known molecular 
weights. As a comparative control recombinant human native TTR was also analysed 
and the retention times obtained for the tetrameric form and monomeric form are 
indicated with vertical arrows. B. HPLC/gel chromatography analysis of sbTTRWT and 
mutants M6 and M12 from several protein batches in which the mutant M12 samples 
had two peaks which had a retention times typical of the tetrameric (17.43 min, smaller 
peak) and the monomeric (23.7 min, higher peak) conformation, respectively.   
Figure 3. Far-UV circular dichroism spectra of pure recombinant human TTR 
(TTRhum) and sbTTRWT, M6 and M12. 
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Figure 4. Analysis of [125I]-T3 binding to sbTTR by native glycine-acetate gel 
electrophoresis. Purified recombinant sbTTRWT, M6 and M12 were incubated at 0 ºC 
for 2 h with labeled [125I]-T3 before running on the gel. A sample of human plasma 
incubated in the same conditions with [125I]T4 was also used to assess TTRs typical 
migration pattern through comparison with the running position of human serum 
albumin. The gel was dried and autoradiographed with 48 h exposure at -80 ºC. The 
first lane shows human plasma which had been incubated with [125I]-T4 before 
electrophoresis and the migration position of human serum albumin (HSA) is indicated; 
the second lane shows the migration position of [125I]-T3 in the absence of TTR; the 
other lanes, as indicated, correspond to the migration pattern of sbTTRWT, M6 an M12 
which before electrophoresis had been incubated with [125I]-T3.  
 
Figure 5. Ligand binding studies of recombinant sbTTRWT and mutants.  
All data represented are the mean (± SE) of duplicate determinations and each assay 
was independently repeated three or more times. A. Purified sbTTR was incubated at 
several different concentrations (0-0.5µg) with 0.1nM [125I] T3 in the absence or 
presence of 10µM unlabeled T3 (for determination of non-specific binding) at 0ºC for 2 
hours.  B. Competitive inhibition of [125I]T3 binding to sbTTRWT (50ng/200 µL) by 
increasing concentrations of unlabeled T3 and T4 (0-10µM). C. Competitive inhibition 
of [125I]T3 binding to sbTTRWT, M12 and M6 by increasing concentrations of cold T3 
ranging from 0 to 10µM. D. Competitive inhibition of [125I]T3 binding to sbTTRWT, 
M12 and M6 by increasing concentrations of cold T4 ranging from 0 to 10µM. Data for 
competition assays is represented as percentage of control (absence of competitor). 
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Figure 6. Scatchard analysis of recombinant sbTTRWT and M6 and M12 binding to 
THs. The plots represent recombinant sbTTRWT, sbTTRM12 and sbTTRM6 binding to 
T3 (A, C and E) and T4 (B, D and F) respectively. Each plot was estimated from 
displacement curves using the softwear Kell-Radlig (Biosoft) and Kd values determined 
are the mean of three or more independent determinations carried out in duplicate in 
each assay.  
 
Figure 7.  Comparison of sbTTRWT, M6 and M12 fibril formation after partial acid 
denaturing at the indicated pHs. Fibrillation for sbTTRWT at pH 3.5 was considered as 
100% and all the other measurements were determined relative to it. Multiple 
comparison statistical analysis between all the samples (n=3) revealed a significant (*) 
increase in fibril formation only for sbTTRWT at pH 3.5 and at both pH 4.5 and 3.5 for 
the mutant M12. As for the mutant M6 no significant increase in fibril formation was 
found at the pHs tested. At pH3.5 and pH4.5 the ability of M6 to produce fibrils was 
residual compared to the WT (p<0.001) and M12 (p<0.001) recombinant proteins, 
respectively.     
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Figure 1   Morgado et al. 
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Figure 2  Morgado et al  
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Figure 3  Morgado et al. 
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Figure 4  Morgado et al.  
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Figure 5  Morgado et al. 
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Figure 6  Morgado et al. 
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Figure 7  Morgado et al. 
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